- 3. Special items
- 4. Sales
- 5. Cost of sales
- 6. Cost of materials
- 7. Personnel expenses
- 8. Selling, general and administrative expenses
- 9. Net interest
- 10. Other financial result
- 11. Taxes
- 12. Earnings per share
3. Special items
The consolidated statement of income for the year 2011 ultimately includes several special items relating to the acquisition of APP Pharmaceuticals, Inc. in 2008. The tables below reconcile adjusted earnings to earnings according to U.S. GAAP in 2011 and 2010.
| € in millions | Other financial result | Net income attributable to Fresenius SE & Co. KGaA |
|---|---|---|
| Earnings 2011, adjusted | 770 | |
| Mandatory Exchangeable Bonds (mark-to-market) | -105 | -85 |
| Contingent Value Rights (mark-to-market) | 5 | 5 |
| Earnings 2011 according to U.S. GAAP |
690 |
| € in millions | Other financial result | Net income attributable to Fresenius SE & Co. KGaA |
|---|---|---|
| Earnings 2010, adjusted | 660 | |
| Mandatory Exchangeable Bonds (mark-to-market) | -98 | -70 |
| Contingent Value Rights (mark-to-market) | 32 | 32 |
| Earnings 2010 according to U.S. GAAP |
622 |
For further information regarding Mandatory Exchangeable Bonds and Contingent Value Rights see note 10, Other financial result.
Continue reading:
4. Sales
4. Sales